EMA's Medicinal Committee Backs Eli Lilly's COVID-19 Antibody Therapy

by Vandana Singh, Benzinga Editor

March 5, 2021 12:51 PM | 1 min read |

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly and Co's (NYSE: LLY) bamlanivimab alone, and bamlanivimab plus etesevimab, in COVID-19 in patients.
The opinion covers the COVID-19 antibody therapy for patients aged 12 years and older who do not require supplemental oxygen and are at high risk of progressing to severe COVID-19.
In February, the antibody therapy received FDA Emergency Use Approval.
Recently, the U.S. government agreed to purchase a minimum of 100,000 doses of antibody therapy, in an agreement valued at $210 million.
Price Action: LLY shares increased 1.9% at $204.32 in market trading hours on the last check Friday.

Posted In: Biotech News Health Care FDA General CHMP Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.